Enoblituzumab, previously known as TJ-271 or MGA271, represents the novel therapeutic specific to CD33, an antigen found predominantly on blood populations. The antibody operates as an bispecific construct, https://lewysknii497816.blog5.net/92503267/enoblituzumab-a-deep-dive-into-tj-271-and-mga271